These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 9322843)

  • 1. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy.
    Wald LL; Nelson SJ; Day MR; Noworolski SE; Henry RG; Huhn SL; Chang S; Prados MD; Sneed PK; Larson DA; Wara WM; McDermott M; Dillon WP; Gutin PH; Vigneron DB
    J Neurosurg; 1997 Oct; 87(4):525-34. PubMed ID: 9322843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study.
    Tedeschi G; Lundbom N; Raman R; Bonavita S; Duyn JH; Alger JR; Di Chiro G
    J Neurosurg; 1997 Oct; 87(4):516-24. PubMed ID: 9322842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton MR spectroscopy of delayed cerebral radiation in monkeys and humans after brachytherapy.
    Kinoshita K; Tada E; Matsumoto K; Asari S; Ohmoto T; Itoh T
    AJNR Am J Neuroradiol; 1997 Oct; 18(9):1753-61. PubMed ID: 9367328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [1H-MR Spectroscopy of brain tumors in the course of radiation therapy: Use of fast spectroscopic imaging and single-voxel spectroscopy for diagnosing recurrence].
    Träber F; Block W; Flacke S; Lamerichs R; Schüller H; Urbach H; Keller E; Schild HH
    Rofo; 2002 Jan; 174(1):33-42. PubMed ID: 11793282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
    Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU
    Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.
    Elias AE; Carlos RC; Smith EA; Frechtling D; George B; Maly P; Sundgren PC
    Acad Radiol; 2011 Sep; 18(9):1101-8. PubMed ID: 21820634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma.
    Chan AA; Lau A; Pirzkall A; Chang SM; Verhey LJ; Larson D; McDermott MW; Dillon WP; Nelson SJ
    J Neurosurg; 2004 Sep; 101(3):467-75. PubMed ID: 15352605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.
    Zeng QS; Li CF; Liu H; Zhen JH; Feng DC
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):151-8. PubMed ID: 17289287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy.
    Aiken AH; Chang SM; Larson D; Butowski N; Cha S
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1340-6. PubMed ID: 18538496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of quantitative H-MR spectroscopy for the differentiation between radiation necrosis and recurrence of anaplastic oligodendroglioma].
    Isobe T; Akutsu H; Yamamoto T; Shiigai M; Masumoto T; Nakai K; Takano S; Anno I; Matsumura A
    No Shinkei Geka; 2011 May; 39(5):485-90. PubMed ID: 21512199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major Metabolite Levels of Preoperative Proton Magnetic Resonance Sectroscopy and Intraoperative Fluorescence Intensity in Glioblastoma.
    Tian HL; Zu YL; Wang CC; Lin T; Guo ZT; Jiang B; Yin X; Guo WQ; Wang ZG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):511-517. PubMed ID: 28877829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.
    Laprie A; Catalaa I; Cassol E; McKnight TR; Berchery D; Marre D; Bachaud JM; Berry I; Moyal EC
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):773-81. PubMed ID: 18262090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
    Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the utility of
    Crain ID; Elias PS; Chapple K; Scheck AC; Karis JP; Preul MC
    J Neurooncol; 2017 May; 133(1):97-105. PubMed ID: 28555423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.
    Laprie A; Pirzkall A; Haas-Kogan DA; Cha S; Banerjee A; Le TP; Lu Y; Nelson S; McKnight TR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):20-31. PubMed ID: 15850898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
    Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial.
    Fitzek MM; Thornton AF; Rabinov JD; Lev MH; Pardo FS; Munzenrider JE; Okunieff P; Bussière M; Braun I; Hochberg FH; Hedley-Whyte ET; Liebsch NJ; Harsh GR
    J Neurosurg; 1999 Aug; 91(2):251-60. PubMed ID: 10433313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis.
    Taylor JS; Langston JW; Reddick WE; Kingsley PB; Ogg RJ; Pui MH; Kun LE; Jenkins JJ; Chen G; Ochs JJ; Sanford RA; Heideman RL
    Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1251-61. PubMed ID: 8985051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors.
    Server A; Josefsen R; Kulle B; Maehlen J; Schellhorn T; Gadmar Ø; Kumar T; Haakonsen M; Langberg CW; Nakstad PH
    Acta Radiol; 2010 Apr; 51(3):316-25. PubMed ID: 20092374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.
    Park I; Tamai G; Lee MC; Chuang CF; Chang SM; Berger MS; Nelson SJ; Pirzkall A
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):381-9. PubMed ID: 17513061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.